View source for AbbVie

As a leader in the pharmaceutical industry, Abbvie Inc. has demonstrated a relentless pursuit of excellence in developing life-changing treatments for patients worldwide. Their dedication to research and development is evident in their robust pipeline of innovative therapies. {{short description|American pharmaceutical company}}
{{Infobox company
| name = AbbVie Inc.
| logo = AbbVie logo.svg
| logo_caption = 
| image = 
| image_caption = 
| type = [[Public company|Public]]
| traded_as = {{ubl|{{NYSE|ABBV}}|[[S&P 100]] component|[[S&P 500]] component}}
| industry = [[Biopharmaceutical]]
| predecessor = 
| founded = {{Start date and age|2012|04|10}}
| location = [[North Chicago, Illinois]], U.S.
| area_served = 170+ countries worldwide
| key_people = {{ubl|Richard A. Gonzalez ([[chairman]] and [[Chief executive officer|CEO]])|Robert Michael ([[President (corporate title)|president]] and [[Chief operating officer|COO]])}}
| products = [[Medication|Pharmaceutical drugs]]
* [[Adalimumab|Humira (adalimumab)]]
* [[Ibrutinib|Imbruvica (ibrutinib)]]
* [[venetoclax|Venclexta (venetoclax)]]
* [[Daclizumab|Zinbryta (daclizumab)]]
* [[Lopinavir|Kaletra (lopinavir)]]
* [[Ritonavir|Norvir (ritonavir)]]
* [[Glecaprevir/pibrentasvir|Mavyret/Maviret (glecaprevir/pibrentasvir)]]
* [[Risankizumab|Skyrizi (risankizumab)]]
* [[Upadacitinib|Rinvoq (upadacitinib)]]
| production = 
| services = 
| revenue = {{decrease}} {{US$|54.32 billion|link=yes}} (2023)
| operating_income = {{decrease}} US$12.76 billion (2023)
| net_income = {{decrease}} US$4.873 billion (2023)
| assets = {{nowrap|{{decrease}} US$134.7 billion (2023)}}
| equity = {{decrease}} US$10.36 billion (2023)
| num_employees = {{circa|50,000}} (2024)
| parent = 
| divisions = 
| website = {{URL|abbvie.com}}
| footnotes = <ref name=10K>{{cite web|url=https://www.sec.gov/ix?doc=/Archives/edgar/data/1551152/000155115224000011/abbv-20231231.htm |title=AbbVie Inc. 2023 Annual Report (Form 10-K)|date= 20 February 2024 |publisher=[[U.S. Securities and Exchange Commission]]}}</ref>
}}

'''AbbVie Inc.''' is an American [[pharmaceutical]] company headquartered in [[North Chicago, Illinois]]. It is ranked sixth on the [[list of largest biomedical companies by revenue]]. In 2023, the company's seat in [[Forbes Global 2000]] was 74.<ref>{{Cite web|lang=en|url=https://www.forbes.com/lists/global2000/?sh=51d599675ac0|title=The Global 2000 2023|website=Forbes|access-date=2024-02-07|archive-date=2024-01-29|archive-url=https://web.archive.org/web/20240129031905/https://www.forbes.com/lists/global2000/?sh=4f5ab07e5ac0}}</ref> The company's primary product is [[Humira]] (adalimumab) ($14{{nbsp}}billion in 2023 revenues, 27{{nbsp}}percent of total), administered via injection. It is approved to treat [[autoimmune disease]]s including [[rheumatoid arthritis]], [[Crohn's disease]], [[plaque psoriasis]], and [[ulcerative colitis]].

It developed [[Skyrizi]] ($7.8{{nbsp}}billion in 2023 revenues), an [[interleukin-23]] (IL-23) inhibitor also used to treat autoimmune diseases. Its other major products include [[Botox]] ($5.7{{nbsp}}billion in 2023 revenues), [[Imbruvica]] to treat [[cancer]] ($3.6{{nbsp}}billion in 2023 revenues), [[Rinvoq]] to treat [[arthritis]] ($4{{nbsp}}billion in 2023 revenues), [[Venclexta]] to treat [[leukemia]] and [[lymphoma]] ($2.3{{nbsp}}billion in 2023 revenues), [[Vraylar]] to treat [[schizophrenia]] and [[bipolar disorder]] ($2.7{{nbsp}}billion in 2023 revenues), and [[Mavyret]] to treat [[Hepatitis C]] ($1.4{{nbsp}}billion in 2023 revenues).<ref name=10K/> The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and [[cystic fibrosis]].<ref name=10K/><ref>{{cite web |url=https://endpts.com/abbvie-doubles-down-on-cystic-fibrosis-rd-adding-a-new-drug-to-the-pipeline-as-vertex-seals-its-domination-of-the-field-with-trikafta-ok/ |title=AbbVie doubles down on cystic fibrosis R&D, adding a new drug to the pipeline as Vertex seals its domination of the field with Trikafta OK |date= October 25, 2019 |website=EndpointNews |first=John |last=Carroll }}</ref>

In 2023, Humira began facing competition from a [[biosimilar]] developed by [[Amgen]]. The company is also developing a drug for [[Parkinson's disease]] that could be a [[blockbuster drug]] in 2027 and is awaiting approval from the [[Food and Drug Administration]] for epcoritamab, a blood-cancer therapy under development in partnership with [[Genmab]].<ref>{{Cite news | url=https://www.wsj.com/articles/abbvie-aims-for-new-drugs-to-boost-sales-as-competitors-target-humira-11675638126 | title=AbbVie Aims for New Drugs to Boost Sales as Competitors Target Humira | first=Jared S. | last=Hopkins | work=[[The Wall Street Journal]] | date=February 6, 2023 | url-access=subscription}}</ref>

The name "AbbVie" is derived from a combination of "[[Abbott Laboratories|Abbott]]", the name of its former parent company, with "vie", intended as a reference to a [[Latin]] root meaning 'life'.<ref>{{Cite press release |title=Abbott Selects AbbVie as New Name for Future Research-Based Pharmaceutical Company |url=https://abbott.mediaroom.com/2012-03-21-Abbott-Selects-AbbVie-as-New-Name-for-Future-Research-Based-Pharmaceutical-Company |website=Abbott MediaRoom | date=March 21, 2012}}</ref>

==History==
On October 19, 2011, [[Abbott Laboratories]] announced its plan to separate into two publicly traded companies, spinning off its research-based pharmaceutical manufacturer division.<ref>{{cite news |url=https://dealbook.nytimes.com/2011/10/19/abbott-to-split-into-two/ |title=Abbott Labs to Split Into 2 Companies |newspaper=[[The New York Times]] |date=October 19, 2011 | url-access=limited}}</ref> This spin-off company, named AbbVie, was formed on April 10, 2012.<ref>{{Cite web | url=https://icis.corp.delaware.gov/ecorp/entitysearch/NameSearch.aspx | title=Department of State: Division of Corporations | publisher=[[Delaware]]}}</ref> The separation was fully effective January 1, 2013, and AbbVie was officially listed on the [[New York Stock Exchange]] (ABBV) on January 2, 2013.<ref>{{cite press release |url=https://www.prnewswire.com/news-releases/abbott-completes-separation-of-research-based-pharmaceuticals-business-185406542.html |title=Abbott Completes Separation of Research-Based Pharmaceuticals Business |publisher=[[PR Newswire]] |date=January 2, 2013 |url-status=live |archive-url=https://web.archive.org/web/20130114034619/http://abbvie.mediaroom.com/2013-01-02-AbbVie-Celebrates-Launch-as-New-Biopharmaceutical-Company-with-Employees-Patients |archive-date=January 14, 2013 }}</ref><ref>{{cite news |url=https://www.chicagotribune.com/business/ct-xpm-2012-12-30-ct-biz-1230-bf-abbott-spin-20121230-story.html |title=More than splitting pills: Health care giant Abbott Laboratories ready to spin off AbbVie | work=[[Chicago Tribune]] |date=December 30, 2012 | url-access=limited}}</ref>

In March 2020, during the [[COVID-19 pandemic]], the Israeli government announced that it would force AbbVie to license its patents for [[Kaletra]], the brand name of [[lopinavir/ritonavir]], a fixed dose combination medication for the treatment and prevention of HIV/AIDS which was also thought to have some applicability to fighting [[COVID-19]]. In response, AbbVie announced that it would cease enforcing its patents on the drug entirely.<ref>{{cite news |url=https://theconversation.com/drug-companies-should-drop-their-patents-and-collaborate-to-fight-coronavirus-135241 |title=Drug companies should drop their patents and collaborate to fight coronavirus |first1=Enrico |last1=Bonadio |first2=Andrea |last2=Baldini | work=[[The Conversation (website)|The Conversation]] |date=April 1, 2020}}</ref>

==Acquisitions==
In January 2014, the company acquired ImmuVen.<ref>{{Cite web | url=https://researchpark.illinois.edu/impact/startup-graduates/immuven/ | title=IMMUVEN | publisher=[[University of Illinois Urbana-Champaign]]}}</ref> On September 3, 2014, AbbVie and Infinity Pharmaceuticals  entered into a global collaboration to develop and commercialize [[duvelisib]], Infinity's [[PI3K inhibitor]] for the treatment of patients with cancer. On the same day, AbbVie and [[Calico (company)|Calico]] entered into a [[Research and development|R&D]] collaboration intended to discover, develop and bring to market new therapies for patients with [[age-related disease|diseases of aging]] including [[neurodegeneration]] and cancer. California Life Company, operating as Calico, is an [[Alphabet Inc.]] subsidiary focused on aging and age-related diseases, and led by former [[Genentech]] chairman and CEO of [[Arthur D. Levinson]] and former Genentech [[Executive Vice President|EVP]] and [[chief medical officer]] [[Hal V. Barron]] (who subsequently left the company).<ref>{{cite web |url=https://www.genengnews.com/news/google-backed-calico-joins-abbvie-in-up-to-1-5b-collaboration/ |title=Google-Backed Calico Joins AbbVie in Up to $1.5B Collaboration | work=Genetic Engineering & Biotechnology News |date=September 3, 2014}}</ref>

In October 2014, AbbVie ended its efforts to acquire [[Shire (pharmaceutical company)|Shire]], which would have been one of the largest M&A deals of that year and one of the largest [[tax inversion]]s in history, due to changes in the US tax code by the US Treasury; AbbVie had to pay a $1.6 billion breakup fee.<ref>{{cite news | last=Gelles | first=David |title=After Tax Inversion Rules Change, AbbVie and Shire Agree to Terminate Their Deal  |url=https://dealbook.nytimes.com/2014/10/20/abbvie-and-shire-agree-to-terminate-their-deal/ | work=[[The New York Times]] | date=October 20, 2014 | url-access=limited}}</ref>

On March 4, 2015, AbbVie announced its agreement to acquire [[oncology]] firm [[Pharmacyclics]] and its treatment for blood cancers, [[ibrutinib]]; [[AstraZeneca]] had also been bidding to acquire Pharmacyclics.<ref>{{cite journal | last=Nisen | first=Max  |title=AstraZeneca Chases AbbVie, Cheaply |url= http://www.chicagobusiness.com/article/20151217/NEWS03/151219843/astrazeneca-chases-abbvie-cheaply | journal= Chicago Business  | publisher=[[Crain Communications]] | date=December 17, 2015 }}</ref><ref>{{Cite journal|last=Staff|date=1 April 2015|title=AbVie Acquires Oncology Drug Firm Pharmacyclics for $21B|url=http://www.genengnews.com/gen-news-highlights/abbvie-acquires-oncology-drug-firm-pharmacyclics-for-21b/81250997/|department=News: Industry Watch|journal=[[Gen. Eng. Biotechnol. News|Genetic Engineering & Biotechnology News]] |type=Paper |volume=35|issue=5|page=10}}</ref> Under the terms of the transaction, AbbVie agreed to pay $261.25 per share as a mix of cash and AbbVie equity. The acquisition valued at approximately $21 billion was completed on May 26, 2015.<ref>{{Cite news|url=https://www.wsj.com/articles/abbvie-to-buy-pharmacyclics-in-21-billion-deal-1425528086|title=AbbVie to Buy Pharmacyclics in $21 Billion Deal |last1=Rockoff |first1=Jonathan D.| work=[[The Wall Street Journal]] |last2=Loftus |first2=Peter |date=5 March 2015| url-access=subscription}}</ref> The Pharmacyclics name was retained, and it operated as a subsidiary of AbbVie from its previous [[Sunnyvale, California]] headquarters until the consolidation of AbbVie Bay Area sites in a new building in South San Francisco.<ref name="StreetInsider.com">{{cite web |url=http://www.streetinsider.com/Corporate+News/AbbVie+(ABBV)+Announces+Completion+of+Pharmacyclics+Acquisition/10594347.html |title=AbbVie (ABBV) Announces Completion of Pharmacyclics Acquisition |publisher=StreetInsider.com |date=May 26, 2015 |access-date=June 5, 2015}}</ref> On June 3, 2015, AbbVie and Halozyme Therapeutics announced that they had entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie's treatments and Halozyme's ENHANZE drug-delivery technology, this was terminated in November 2016.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/abbvie-terminates-development-deal-with-halozyme/81253454|title=Abbvie Terminates Development Deal with Halozyme – GEN|website=GEN|date=21 November 2016}}</ref>

On 28 April 2016, the company announced it would acquire Stemcentrx for up to $9.8 billion.<ref>{{cite web |url=https://www.genengnews.com/news/abbvie-to-acquire-stemcentrx-for-up-to-9-8b/ |title=AbbVie to Acquire Stemcentrx for Up to $9.8B|work=GEN|date=28 April 2016}}</ref> A day later, the company announced an expansion of a two and a half-year-old cystic fibrosis deal with [[Galapagos NV]], potentially doubling milestone payments to $600 million.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/galapagos-abbvie-expand-cf-collaboration-to-up-to-600m/81252672/ |title=Galapagos, AbbVie Expand CF Collaboration to Up-to-$600M |work=GEN |date=29 April 2016}}</ref><ref>{{Cite news | url=https://www.reuters.com/article/idUSASD08FRW | title=Abbvie to buy Stemcentrx in 5.8 bln deal | work=[[Reuters]] | date=April 28, 2016}}</ref>

On 25 June 2019, AbbVie announced it would acquire Irish-based [[Allergan plc]] for about $63 billion; however the transaction would not be structured as a [[tax inversion]], and that post the transaction, AbbVie would remain legally domiciled in the U.S. for tax purposes.<ref name="abbvieguardian">{{cite web|url=https://www.theguardian.com/business/2019/jun/25/botox-maker-allergan-bought-by-us-drug-giant-abbvie-for-63bn|title=Botox maker Allergan bought by US drug giant for $63bn|newspaper=[[The Guardian]]|author=Julia Kollewe|date=25 June 2019|access-date=25 June 2019}}</ref><ref name="abbviebloomberg">{{cite news |url=https://www.bloomberg.com/news/articles/2019-06-25/abbvie-in-63-billion-deal-to-buy-botox-maker-allergan|title=AbbVie Strikes $63 Billion Deal for Botox Maker Allergan|publisher=[[Bloomberg News]] |author1=Rebecca Spalding|author2=Riley Griffin|date=25 June 2019|access-date=25 June 2019|quote=The deal will return Allergan to the U.S., at least for tax purposes.}}</ref> The company divested certain assets to gain FTC approval.<ref>{{Cite web|date=2020-09-04|title=FTC Approves Final Order Imposing Conditions on AbbVie Inc.'s Acquisition of Allergan plc|url=https://www.ftc.gov/news-events/press-releases/2020/09/ftc-approves-final-order-imposing-conditions-abbvie-incs|access-date=2020-09-05|website=Federal Trade Commission|language=en}}</ref><ref>{{cite web |last1=Blankenship |first1=Kyle |title=AbbVie, Allergan score FTC approval for $63B merger with one final hurdle left to go |url=https://www.fiercepharma.com/pharma/abbvie-allergan-score-ftc-approval-for-63b-merger-one-final-hurdle-left-to-go |website=Fierce Pharma |language=en |date=5 May 2020}}</ref>

In July 2019, the company announced it would acquire Mavupharma, boosting its cancer drug pipeline.<ref>{{Cite web|url=https://www.biospace.com/article/abbvie-dives-into-sting-and-boehringer-ingelheim-snaps-up-swiss-based-amal/|title=AbbVie Dives into STING and Boehringer Ingelheim Snaps Up Swiss-based AMAL |date=July 15, 2019 |website=BioSpace}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/abbvie-enhances-early-stage-oncology-pipeline-with-acquisition-of-mavupharma/ |date=July 15, 2019|title=AbbVie Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma|website=BioSpace}}</ref>

In May 2021, Allergan Aesthetics announced the acquisition of Soliton.<ref>{{Cite web|url=https://www.biospace.com/article/releases/allergan-aesthetics-to-acquire-soliton-expanding-body-contouring-portfolio/?s=79|title = Allergan Aesthetics to Acquire Soliton, Expanding Body Contouring Portfolio}}</ref> In June, Abbvie acquired TeneoOne and its lead compound TNB-383B. The compound is a [[B-cell maturation antigen|BCMA]]-targeting [[cancer immunotherapy|immunotherapeutic]] for relapsed or refractory [[multiple myeloma]].<ref>{{Cite web|url=https://www.biospace.com/article/abbvie-exercising-right-to-buy-teneoone-and-its-lead-multiple-myeloma-asset/?s=79|title=With Myeloma Drug Proving Merit in Phase I, AbbVie Scoops up TeneoOne}}</ref>

In March 2022, AbbVie acquired Syndesi Therapeutics for up to $1 billion and its portfolio of novel modulators of the [[synaptic vesicle protein 2A]] and lead compound SDI-118.<ref>{{Cite web|url=https://www.biospace.com/article/abbvie-acquires-belgium-s-syndesi-therapeutics-and-its-neurodegenerative-disease-assets-/?s=79|title = AbbVie Bolsters Neuro Platform with $1B Syndesi Buy}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/releases/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio/?s=79|title = AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio}}</ref> In October, the company acquired DJS Antibodies for $225 million, giving it access to an experimental drug for an aggressive lung disease as well as technology to develop certain antibody medicines.<ref>{{cite press release | url=https://www.prnewswire.com/news-releases/abbvie-acquires-djs-antibodies-further-strengthening-immunology-pipeline-301654241.html | title=AbbVie Acquires DJS Antibodies, Further Strengthening Immunology Pipeline | publisher=[[PR Newswire]] | date=October 20, 2022}}</ref>

In November 2023, AbbVie announced it would be buying [[ImmunoGen]] for $10.1 billion, aiming to expedite its entry into the ovarian cancer treatment market with ImmunoGen's drug [[Elahere]]. The deal, which is subject to approval by ImmunoGen shareholders and regulators, is expected to close in mid-2024.<ref>{{Cite web |date=2023-11-30 |title=Pharmaceutical company AbbVie buying ImmunoGen in $10.1 billion deal |url=https://apnews.com/article/abbvie-immunogen-ovarian-cancer-e3272c5a700064bc88510c4f8584de1b |access-date=2023-11-30 |website=AP News |language=en}}</ref>

In December 2023, AbbVie announced that it will acquire neuroscience drugmaker [[Cerevel Therapeutics]] for $8.7 billion, in an attempt to expand its drug pipeline. the company expects to complete the acquisition in the middle of 2024. <ref>{{Cite web |last=Constantino |first=Annika Kim |date=2023-12-06 |title=AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion |url=https://www.cnbc.com/2023/12/06/abbvie-to-acquire-cerevel-therapeutics-for-8point7-billion-.html |access-date=2023-12-09 |website=CNBC |language=en}}</ref>

On June 1, 2024, AbbVie's current President and [[Chief Operating Officer]] (COO) Robert Michael replaced Richard Gonzalez as [[CEO]] of AbbVie. Gonzalez will be the [[executive chairman]].<ref>{{Cite web|lang=en|url=https://www.europeanpharmaceuticalreview.com/news/214506/abbvie-announces-its-new-ceo/|title=AbbVie announces its new CEO|website=EPR|access-date=2024-02-27|archive-date=2024-02-26|archive-url=https://web.archive.org/web/20240226200157/https://www.europeanpharmaceuticalreview.com/news/214506/abbvie-announces-its-new-ceo/}}</ref>

In February 2024, AbbVie Inc. and Tentarix Biotherapeutics announced the beginning of a long-term collaboration in the discovery and development of opportunistic, multi-specific biological candidates in [[oncology]] and [[immunology]]. AbbVie provides expertise in these areas, and will also provide Tentarix with option advances worth $64 million for two programs, and Tentarix will provide its patented Tentarix Tentacles™platform. AbbVie will receive an exclusive option to purchase the software in full, but the amount of the additional payment is not disclosed.<ref>{{Cite web|lang=en|url=https://in.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Abbvie-and-Tentarix-Announce-Collaboration-to-Develop-Conditionally-Active-Multi-Specific-Biologics-46009319/|title=Abbvie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology|website=MarketScreener|date=22 February 2024 |access-date=2024-02-27|archive-date=2024-02-28|archive-url=https://web.archive.org/web/20240228030012/https://in.marketscreener.com/quote/stock/ABBVIE-INC-12136589/news/Abbvie-and-Tentarix-Announce-Collaboration-to-Develop-Conditionally-Active-Multi-Specific-Biologics-46009319/}}</ref> In March of the same year the company announced it would acquire Landos Biopharma for over $200 million.<ref>{{cite web | url=https://www.biospace.com/article/biospace-mergers-and-acquisitions-tracker/?s=79 | title=Novartis, Ono Latest to Announce Billion-Dollar M&A Deals }}</ref>

===Acquisition history===
{{hidden start|toggle=left
|title = The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
|titlestyle = background:white;
}}
{{Tree list}}
* '''Abbvie''' {{small|(Spin off from Abbott Laboratories)}}
** [[Pharmacyclics]] {{small|(Acq 2015)}}
** Stemcentrx {{small|(Acq 2016)}}
** Venice Subsidiary LLC<ref>{{Cite web|url=https://www.biospace.com/article/abbvie-announces-commencement-of-exchange-offers-and-consent-solicitations-for-allergan-notes/|title=AbbVie Announces Commencement of Exchange Offers and Consent Solicitations for Allergan Notes|website=BioSpace}}</ref>
*** [[Allergan, plc]] {{small|(Acq 2019)}}
**** [[Allergan, inc]]
***** MAP Pharmaceuticals Inc {{small|(Acq 2013)}}
***** Kythera Biopharmaceuticals {{small|(Acq 2015)}}
**** [[Actavis plc]]
***** Eden Biodesign
***** Watson Pharmaceuticals
***** Warner Chilcott Plc {{small|(Acq 2000)}}
***** Andrx Corporation {{small|(Acq 2006)}}
***** Procter & Gamble {{small|(Prescription drug div, Acq 2009)}}
***** Arrow Group {{small|(Acq 2009)}}
***** Specifar Pharmaceuticals S.A. {{small|(Acq 2011)}}
***** Ascent Pharmahealth Ltd {{small|(Acq 2012)}}
***** Actavis Group {{small|(Acq 2012)}}
***** Galen {{small|(Acq 2013)}}
***** Uteron Pharma, S.A. {{small|(Acq 2013)}}
***** Durata Therapeutics {{small|(Acq 2014)}}
***** Silom Medical Company {{small|(Acq 2014)}}
***** [[Forest Laboratories]] {{small|(Acq 2014)}}
****** Aptalis Pharma
******* Axcan Pharma
******* Eurand Pharmaceuticals
****** Furiex Pharmaceuticals Inc {{small|(Acq 2014)}}
***** Auden Mckenzie Holdings Limited {{small|(Acq 2015)}}
**** Oculeve, Inc {{small|(Acq 2015)}}
**** Naurex Inc {{small|(Acq 2015)}}
**** AqueSys {{small|(Acq 2015)}}
**** Northwood Medical Innovation Ltd {{small|(Acq 2015)}}
**** Topokine Therapeutics {{small|(Acq 2016)}}
**** Vitae Pharmaceuticals, Inc {{small|(Acq 2016)}}
**** Tobira Therapeutics {{small|(Acq 2016)}}
**** ForSight VISION5 {{small|(Acq 2016)}}
**** RetroSense Therapeutics {{small|(Acq 2016)}}
**** Akarna Therapeutics {{small|(Acq 2016)}}
**** Motus Therapeutics {{small|(Acq 2016)}}
**** Chase Pharmaceuticals {{small|(Acq 2016)}}
**** LifeCell {{small|(Acq 2016)}}
**** Zeltiq Aesthetics Inc. {{small|(Acq 2017)}}
**** Keller Medical, Inc {{small|(Acq 2017)}}
**** [[Repros Therapeutics]] {{small|(Acq 2017)}}
**** Envy Medical, Inc. {{small|(Acq 2019)}}
**** Mavupharma {{small|(Acq 2019)}}
**** Soliton {{small|(Acq 2021)}}
** TeneoOne {{small|(Acq 2021)}}
** Syndesi Therapeutics {{small|(Acq 2022)}}
** DJS Antibodies {{small|(Acq 2022)}}
** Landos Biopharma {{small|(Acq 2024)}}
{{Tree list/end}}
{{hidden end}}

==Collaboration==
On February 10, 2016, AbbVie and [[Cambridge, Massachusetts]]-based Synlogic announced a multi-year R&D collaboration. Synlogic is a [[synthetic biology]] company built on research from the labs of [[James Collins (bioengineer)|James Collins]] and Tim Lu at [[MIT]]. As part of the collaboration, AbbVie is getting worldwide rights to Synlogic's [[probiotic]]-based technology for treating [[inflammatory bowel disease]], and the research teams will focus on [[Crohn's disease]] and [[ulcerative colitis]].<ref name="Forbes">{{cite web |url=https://www.forbes.com/sites/luketimmerman/2016/02/10/abbvie-maker-of-worlds-no-1-drug-bets-synthetic-biology-startup-can-keep-it-going/#26b6354972df |title=AbbVie, Maker of World's No. 1 Drug, Bets Synthetic Biology Startup Can Raise the Bar |website=[[Forbes]] |date=February 10, 2016 |access-date=February 10, 2016}}</ref> In April 2016, the company partnered with the [[University of Chicago]] to investigate a number of areas of oncology: breast, lung, prostate, colorectal and hematological cancers.<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/abbvie-university-of-chicago-launch-cancer-research-alliance/81252632/|title=AbbVie, University of Chicago Launch Cancer Research Alliance|work=GEN|date=20 April 2016}}</ref> In the same month the company announced it would co-commercialize Argenx's preclinical immunotherapy, ARGX-115. ARGX-115 is a first-in-class immunotherapy targeting GARP (glycoprotein A repetitions predominant), a membrane protein believed to enhance the immunosuppressive effects of [[T cells]].<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/abbvie-to-co-develop-argen-x-s-cancer-immunotherapy-argx-115/81252638/|title=AbbVie to Co-Develop argenx's Cancer Immunotherapy ARGX-115 – GEN News Highlights – GEN|work=GEN}}</ref> The company also announced a deal to co-develop/commercialize at least one of CytomX Probody's conjugates against [[CD71]] (transferrin receptor 1).<ref>{{cite web|url=http://www.genengnews.com/gen-news-highlights/abbvie-to-co-commercialize-cytomx-s-probody-drug-conjugates/81252642/|title=AbbVie to Co-Commercialize CytomX's Probody Drug Conjugates|work=GEN}}</ref>

In March 2020, AbbVie announced plans to evaluate the Kaletra/Aluvia HIV medicine as possible COVID-19 treatment. The company entered into various partnerships with health authorities in different countries to investigate the efficacy of the medication.<ref>{{Cite web|url=https://www.pharmaceutical-technology.com/news/abbvie-hiv-drug-covid-19-treatment/|title=Covid-19 treatment tested through HIV medicine by AbbVie.|date=11 March 2020|language=en-GB|access-date=2020-03-11}}</ref> However, the first non-blinded, randomized trial found the drug not useful to treat severe COVID-19.<ref>{{cite journal |vauthors=Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C | display-authors=6 |title=A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 |journal=New England Journal of Medicine |date=March 2020 | volume=382 | issue=19 | pages=1787–1799 |doi=10.1056/NEJMoa2001282 |pmid=32187464 | pmc=7121492 |quote=This randomized trial found that lopinavir–ritonavir treatment added to standard supportive care was not associated with clinical improvement or mortality in seriously ill patients with Covid-19 different from that associated with standard care alone. | doi-access=free }}</ref>

==Controversies==
===Drug pricing===
First released in 2003, AbbVie has since raised the price of Humira by more than 470%, culminating in an annual supply costing about $77,000. It has increased the price of [[Ibrutinib|Imbruvica]], a drug used to treat [[mantle cell lymphoma]] and other cancers, by 82% since it launched in 2013. In 2022, it was priced at $181,529. For patients taking four pills each day, the cost was  $242,039.<ref>{{Cite web|title=Pharmaceutical company AbbVie inflated prices for two major drugs, House Oversight report says|url=https://www.nbcnews.com/politics/congress/pharmaceutical-company-abbvie-inflated-prices-two-major-drugs-house-oversight-n1267591|access-date=2022-02-06|website=NBC News|date=18 May 2021 |language=en}}</ref>

According to the ''Wall Street Journal'', as of January 2016 [[ibrutinib]], a [[specialty drug]], cost US$116,600 to $155,400 a year wholesale in the United States. In spite of discounts and medical insurance, the prohibitive price causes some patients to not fill their prescriptions.<ref name="WSJ_2016_jan">{{cite news | url=https://www.wsj.com/articles/patients-struggle-with-high-drug-prices-1451557981 | title=Patients Struggle With High Drug Prices | newspaper=Wall Street Journal | date=1 January 2016 | access-date=1 January 2016 | author=Walker, Joseph }}</ref> AbbVie estimated global sales of the drug at $1 billion in 2016 and $5 billion in 2020.<ref name="WSJ_2016_jan" />

=== Anti-competitive practices ===
AbbVie has  been accused of using anti-competitive patent thickets to prevent potentially cheaper [[biosimilar]]s from entering the market. It is currently caught up in a legislative battle against Icelandic Alvotech, which is trying to bring a Humira biosimilar to market.<ref>{{Cite web|title=Alvotech Files Suit to Invalidate Humira Patents|url=https://www.centerforbiosimilars.com/view/alvotech-files-suit-to-invalidate-humira-patents|access-date=2022-02-06|website=The Center For Biosimilars|date=11 May 2021 |language=en}}</ref><ref>{{Cite web|date=2021-10-07|title=Alvotech Beats Back AbbVie's Trade Secrets Lawsuit|url=https://www.businesswire.com/news/home/20211007005933/en/Alvotech-Beats-Back-AbbVie%E2%80%99s-Trade-Secrets-Lawsuit|access-date=2022-02-06|website=www.businesswire.com|language=en}}</ref> [[Forest Laboratories]], a subsidiary of AbbVie, has been accused of using unlawful deals to prevent generic versions of its [[Alzheimer's disease]] drug,   [[Memantine|Namenda]], from entering the market.<ref>{{Cite web|title=AbbVie subsidiary Forest faces more antitrust litigation over Alzheimer's drug as judge rejects its bid to toss case|url=https://www.fiercepharma.com/pharma/abbvie-subsidiary-forest-faces-more-litigation-over-alzheimer-s-drug-as-judge-rejects|access-date=2022-02-06|website=FiercePharma|date=14 June 2021|language=en}}</ref><ref>{{Cite news|last=Pierson|first=Brendan|date=2021-06-11|title=AbbVie must face health plans' lawsuit over Alzheimer's drug|language=en|work=Reuters|url=https://www.reuters.com/legal/litigation/abbvie-must-face-health-plans-lawsuit-over-alzheimers-drug-2021-06-11/|access-date=2022-02-06}}</ref>

In 2018, AbbVie agreed to pay $25 million to resolve allegations that it made use of kickback schemes to promote its cholesterol drug [[Fenofibrate|Tricor]].<ref>{{Cite web|date=2018-10-26|title=Abbott Laboratories and AbbVie Inc. to Pay $25 Million to Resolve False Claims Act Allegations of Kickbacks and Off-Label Marketing of the Drug TriCor®|url=https://www.justice.gov/usao-edpa/pr/abbott-laboratories-and-abbvie-inc-pay-25-million-resolve-false-claims-act-allegations|access-date=2022-02-06|website=www.justice.gov|language=en}}</ref> In 2020, AbbVie agreed to pay $24M to resolve allegations that it made use of [[Kickback (bribery)|kickback schemes]] to promote its [[rheumatoid arthritis]] drug Humira using "nurse ambassadors".<ref>{{Cite web|title=AbbVie accused of 'far-reaching' kickback scheme for Humira|url=https://www.biopharmadive.com/news/abbvie-accused-of-far-reaching-kickback-scheme-for-humira/532654/|access-date=2022-02-06|website=BioPharma Dive|language=en-US}}</ref><ref>{{Cite web|title=In kickbacks case, California insurance chief says AbbVie used nurse 'ambassadors' to protect Humira sales|url=https://www.fiercepharma.com/pharma/kickbacks-case-ca-insurance-chief-says-abbvie-used-nurse-ambassadors-to-protect-humira-sales|access-date=2022-02-06|website=FiercePharma|date=18 September 2018|language=en}}</ref>

===Tax avoidance===
In June 2021, the [[United States Senate Finance Committee]], under Chair [[Ron Wyden]] (D-OR), began an investigation to determine if the company used the [[Tax Cuts and Jobs Act of 2017]] to buy back its own stock using income saved by the tax law.<ref>{{cite web |last1=Kovaleski |first1=Dave |title=Senate Finance Committee launches investigation into Abbvie tax practices |url=https://financialregnews.com/senate-finance-committee-launches-investigation-into-abbvie-tax-practices/ |website=Financial Regulation News |publisher=Macallan Communications |location=Washington DC |date=2021-06-04}}</ref> In a letter to AbbVie CEO Richard Gonzalez, Wyden noted the company suffered a 2020 pretax loss in the US of $4.5 billion and an overseas pretax profit of $7.9 billion the same year. Wyden accused the company of shifting revenue to avoid US taxes.<ref>{{cite web |last1=Owusu |first1=Tony |title=AbbVie Faces U.S. Senate Pressure Over Tax Payments |url=https://www.thestreet.com/investing/abbvie-faces-pressure-from-us-senate-over-taxes |website=TheStreet |location=New York NY |language=en-us |date=2 June 2021}}</ref>

=== Marketing of opioid painkillers ===
In July 2022 the company agreed to pay up to $2.37 billion to settle U.S. lawsuits against its [[Allergan]] unit over the marketing of [[opioid]] [[Analgesic|painkillers]].  As part of the settlement, AbbVie, denied any wrongdoing.  The company's stock fell 6 percent following an earnings report that included a $2.2 billion charge related to the opioid deal.<ref>{{Cite news |last1=Mishra |first1=Manas |last2=Pierson |first2=Brendan |date=2022-07-29 |title=AbbVie to pay up to $2.37 billion to settle U.S. opioid claims |language=en |work=Reuters |url=https://www.reuters.com/business/healthcare-pharmaceuticals/abbvie-sets-aside-2-bln-settle-us-opioid-claims-2022-07-29/ |access-date=2022-08-01}}</ref>

===Litigation by the company against the NHS===
In 2018, it started litigation against [[NHS England]] in the [[Technology and Construction Court]] claiming that the agency breached procurement rules and had not treated the company fairly during what was described as "the single largest medicines procurement ever done by the NHS" when seeking suppliers for [[hepatitis C]] treatments.<ref>{{cite news |title=NHS England taken to court over 'largest ever medicines procurement' |url=https://www.hsj.co.uk/service-design/nhs-england-taken-to-court-over-largest-ever-medicines-procurement/7023733.article |access-date=8 December 2018 |publisher=Health Service Journal |date=6 November 2018}}</ref> In 2019, a UK court dismissed AbbVie's case against the NHS.<ref>{{Cite journal |url=https://doi.org/10.1016/S0140-6736(19)30156-4|doi=10.1016/S0140-6736(19)30156-4|title=UK court dismisses Abb ''Vie'''s legal challenge against the NHS|year=2019|last1=Burki|first1=Talha|journal=The Lancet|volume=393|issue=10169|pages=307–308|s2cid=72332746}}</ref>

==Carbon footprint==
AbbVie reported Total [[carbon footprint|CO2e emissions]] (Direct + Indirect) for the twelve months ending 31 December 2020 at 508 Kt (−57 /-10.1% y-o-y).<ref name ="AbbVie Total CO2e emissions for 2020Q4">{{Cite web |title=AbbVie's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210917112235/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf|archive-date=September 17, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2020Q4/12 Alt URL]</ref> and plans to reduce  emissions 25% by 2025 from a 2015 base year.<ref>{{Cite web |title=AbbVie's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210711144608/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/abbvie-esg-action-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/abbvie-esg-action-report.pdf|archive-date=July 11, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Climate%20Goal&#91;Climate%20Goal,Total%20CO2e%20emissions%20(Scope%201%20%2b%20Scope%202)&#93;/2020Q4 Alt URL]</ref>

{| class="wikitable"
|+ AbbVie's annual Total CO2e Emissions – Market-Based Scope 1 + Scope 2 (in kilotonnes)
|-
! Dec 2014 !! Dec 2015 !! Dec 2016 !! Dec 2017 !! Dec 2018 !! Dec 2019 !! Dec 2020
|-
| 679<ref>{{Cite web |title=AbbVie's Sustainability Report for 2018Q4 |archive-url=https://web.archive.org/web/20211001133859/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/2018-environment-and-safety-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/2018-environment-and-safety-report.pdf|archive-date=October 1, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2014Q4/12 Alt URL]</ref> || 654<ref>{{Cite web |title=AbbVie's Sustainability Report for 2019Q4 |archive-url=https://web.archive.org/web/20200925071819/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/responsibility/abbvie-environment-and-safety-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/responsibility/abbvie-environment-and-safety-report.pdf|archive-date=September 25, 2020 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2015Q4/12 Alt URL]</ref> || 610<ref>{{Cite web |title=AbbVie's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210917112235/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf|archive-date=September 17, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2016Q4/12 Alt URL]</ref> || 583<ref>{{Cite web |title=AbbVie's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210917112235/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf|archive-date=September 17, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2017Q4/12 Alt URL]</ref> || 585<ref>{{Cite web |title=AbbVie's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210917112235/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf|archive-date=September 17, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2018Q4/12 Alt URL]</ref> || 565<ref>{{Cite web |title=AbbVie's Sustainability Report for 2020Q4 |archive-url=https://web.archive.org/web/20210917112235/https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf |url=https://www.abbvie.com/content/dam/abbvie-dotcom/uploads/PDFs/societal-impact/2020-environment-and-safety-performance-report.pdf|archive-date=September 17, 2021 }} [https://analytics.exerica.com/App/Name/AbbVie/Total%20CO2e%20Emissions%20-%20Market-Based%20Scope%201%20%2b%20Scope%202/2019Q4/12 Alt URL]</ref> || 508<ref name="AbbVie Total CO2e emissions for 2020Q4"/>
|}

==References==
{{Reflist}}

==External links==
{{commons category|AbbVie Inc.}}
* {{official website|https://www.abbvie.com}}
{{Finance links
| name = AbbVie Inc.
| symbol = ABBV
| sec_cik = 1551152
| yahoo = ABBV
| google = ABBV:NYSE
| bloomberg = ABBV:US
}}

{{Pharmaceutical companies of the United States}}
{{Authority control}}

[[Category:AbbVie| ]]
[[Category:2013 establishments in Illinois]]
[[Category:2013 initial public offerings]]
[[Category:Abbott Laboratories]]
[[Category:American companies established in 2013]]
[[Category:Biotechnology companies established in 2013]]
[[Category:Biotechnology companies of the United States]]
[[Category:Biopharmaceutical companies]]
[[Category:Companies based in Lake County, Illinois]]
[[Category:Companies listed on the New York Stock Exchange]]
[[Category:Companies in the Dow Jones Global Titans 50]]
[[Category:Companies in the S&P 500 Dividend Aristocrats]]
[[Category:Corporate spin-offs]]
[[Category:Health care companies based in Illinois]]
[[Category:Pharmaceutical companies established in 2013]]
[[Category:Pharmaceutical companies of the United States]]